_MACHINE TRANSLATION_
The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), with reference to Current Report ESPI No. 49/2025 of 5 December 2025, hereby informs that it has received confirmation that the Issuer’s attorney has submitted to the European Medicines Agency (“EMA”) the documentation containing all clarifications and responses to EMA’s questions within the ongoing procedure related to the application for a positive recommendation for the granting of a Marketing Authorisation (“MA”) for the veterinary medicinal product BCX‑CM‑J intended for the treatment of osteoarthritis in dogs.
According to the schedule, the list of additional questions from EMA will be provided to the Issuer by 15 July 2026. The Issuer will inform about further progress of the above‑mentioned administrative procedure in separate communications after reviewing EMA’s position.
The Management Board of the Issuer has considered the above information significant due to the crucial importance of the MA approval process for the BCX‑CM‑J product in the context of its commercialisation, as well as the potential impact of this information on the assessment of the Issuer’s financial instruments.
Signatures of persons representing the Company:
Łukasz Bzdzion – President of the Management Board
Paweł Wielgus – Member of the Management Board